Jump to content

Factor XII

From Wikipedia, the free encyclopedia
(Redirected from Coagulation factor XIIa)

F12
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesF12, HAE3, HAEX, HAF, coagulation factor XII
External IDsOMIM: 610619; MGI: 1891012; HomoloGene: 425; GeneCards: F12; OMA:F12 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2161

58992

Ensembl

ENSG00000131187

ENSMUSG00000021492

UniProt

P00748

Q80YC5

RefSeq (mRNA)

NM_000505

NM_021489

RefSeq (protein)

NP_000496

NP_067464

Location (UCSC)Chr 5: 177.4 – 177.42 MbChr 13: 55.57 – 55.57 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Coagulation factor XII, also known as Hageman factor, is a plasma protein involved in coagulation. It is the zymogen form of factor XIIa (EC 3.4.21.38), an enzyme of the serine protease (or serine endopeptidase) class. In humans, factor XII is encoded by F12 gene.[5]

Genetics

[edit]

The gene for factor XII is located on the tip of the long arm of the fifth chromosome (5q33-qter).[5]

Structure

[edit]

Human Factor XII is 596 amino acids long and consists of two chains, the heavy chain (353 residues) and light chain (243 residues) held together by a disulfide bond. It is 80,000 daltons in molecular weight. The heavy chain contains two fibronectin-type domains (type I and II), two epidermal growth factor-like domains, a kringle domain, and a proline-rich region, while the light chain contains the protease domain. FXII can be cleaved sequentially at two sites, Arg353 and Arg334, with the second cleavage liberating the light chain and forming β-FXIIa.[6]

The structure of the FnI-EGF-like tandem domain of coagulation factor XII has been solved by X-ray crystallography.[7][8] Crystal structures of the FXII light chain have also been determined, both unbound (β-FXII) and bound (β-FXIIa) to inhibitors.[9][10][11]

Function

[edit]
The coagulation cascade.

Factor XII (FXII, Hageman factor) is a plasma glycoprotein of approximately 90 kDa and is part of the coagulation cascade. It activates factor XI and prekallikrein in vitro. FXII is activated to FXIIa by negatively charged surfaces such as glass, initiating the intrinsic pathway.[12] FXII also plays a role in diagnostic coagulation assays called activated partial thromboplastin times (aPTT).[13]

In vivo, FXII is activated by binding to polyanions in a process termed contact activation. Various polymers, such as kaolin and glass, act as non-physiological activators of FXII. Activated platelets release inorganic polyphosphates, which activate FXII, initiating the intrinsic pathway and contributing to fibrin formation and thrombus development.[14] Polyphosphates also accelerate thrombin-induced activation of factor XI.[15]

Polyphosphate forms calcium-rich nanoparticles in vivo, which accumulate on platelets and activate FXII. The regulation of platelet polyphosphates is still not fully understood, but the phosphate-exporter XPR1 has been identified as a key regulator.[16] Targeting XPR1 increases polyphosphate levels, accelerating thrombosis in mouse models.[17]

Given FXII’s role in thrombosis while sparing hemostasis, it has become a target for anticoagulant drug development. Inhibitors targeting FXII are in clinical trials.[18]

Clinical significance

[edit]
Main article: Factor XII deficiency

Factor XII deficiency is a rare disorder that is inherited in an autosomal recessive manner.[19] Unlike other clotting factor deficiencies, factor XII deficiency is totally asymptomatic and does not cause excess bleeding.[19] Mice lacking the gene for factor XII, however, are less susceptible to thrombosis. The protein seems to be involved in the later stages of clot formation rather than the first occlusion of damages in the blood vessel wall.[20]

Factor XII does play an important role in clot formation during in vitro measurements of the partial thromboplastin time, which causes these measurements to be markedly prolonged in patients with factor XII deficiency, usually well beyond even what is seen in hemophilia A, hemophilia B, or factor XI deficiency.[19] As a result, the main concern related to factor XII deficiency is the unnecessary testing, delay in care, worry, etc. that may be prompted by the abnormal lab result.[19] All of this, including the mechanism of inheritance, also holds true for the other contact factors, prekallikrein (Fletcher factor) and high molecular weight kininogen.[19]

Excess levels of factor XII can predispose individuals towards greater risk of venous thrombosis due to factor XII's role as one of the catalysts for conversion of plasminogen to its active fibrinolytic form of plasmin.[21]

Factor XII is also activated by endotoxins, especially lipid A in vitro. Experimental mouse models have suggested a role of FXII in multiple sclerosis.[22]

History

[edit]

Hageman factor was first discovered in 1955 when a routine preoperative blood sample of the 37-year-old railroad brakeman John Hageman (1918) was found to have prolonged clotting time in test tubes, even though he had no hemorrhagic symptoms. Hageman was then examined by hematologist Oscar Ratnoff, who found that Hageman lacked a previously unidentified clotting factor.[23] Ratnoff later found that the Hageman factor deficiency is an autosomal recessive disorder, after examining several related people who had the deficiency. Paradoxically, pulmonary embolism contributed to Hageman's death after an occupational accident in 1968. Since then, case studies and clinical studies identified an association between thrombosis and Factor XII deficiency. Hepatocytes express blood coagulation factor XII.[24]

Currently produced QuikClot products, produced and marketed primarily for use in battlefield medicine to treat penetrating trauma (such as gunshot wounds and stab wounds), and other injuries that are known to commonly cause exsanguination (such as blast injury), are used with the overarching goal of increasing the time between the blood loss occurring, and the patient succumbing to the blood loss. The purpose of increasing this time is so that the patient may reaching a higher level of medical care before succumbing from their injuries. These products use a Kaolinite-based coating, applied to the bandages by the manufacturer before packaging and sale. This coating, when applied to an open wound via the application of the bandages, directly promotes blood clotting by activating Factor XII in the coagulation cascade.[25] Also, due to the active ingredient nature of Kaolinite, the activation of the Factor XII occurs in both an earlier amount of time than it otherwise would, and at an increased, more rapid rate than it otherwise would.[26][27] This coating is widely considered amongst combat medics to be vastly superior to the older QuikClot powder formulation, which was poured into wounds, due to the fact that the older formulation used bead-form Zeolite, a mineral which promotes the coagulation cascade, due to the fact that the reaction between the Zeolite powder and the blood inside the wound site was an Exothermic one, sometimes so intensely that it caused cases of second degree burns on the inside surface of the wound. This, obviously, caused extreme pain to the patient, often more-so than the initial injury was causing them at the time (assuming the patient was still conscious at the time of the application of the powder).[28] This effect is often seen in movies and TV programs, with the QuikClot powder being poured into wounds, and the patient screaming out in pain as their wounds were violently burned on the inside surface of the wounds. This created a common misconception, which persists to this day, that commonly used QuikClot products still use this method of clot promotion (Zeolite powder) to this day. However, Zeolite-based clotting products are no longer widely used by militaries and police departments throughout the western world, as they have been widely supplanted by the Kaolinite-based bandage products, which do not cause any exothermic reaction whatsoever, nor do they have the absolute-requirement of the application of the product exclusively to the inside-surface of the wound.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000131187 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000021492 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b Cool DE, MacGillivray RT (October 1987). "Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region". The Journal of Biological Chemistry. 262 (28): 13662–13673. doi:10.1016/S0021-9258(19)76478-3. PMID 2888762.
  6. ^ Ivanov I, Matafonov A, Gailani D (September 2017). "Single-chain factor XII: a new form of activated factor XII". Current Opinion in Hematology. 24 (5): 411–418. doi:10.1097/MOH.0000000000000363. PMC 5762122. PMID 28604413.
  7. ^ Stavrou E, Schmaier AH (March 2010). "Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis". Thrombosis Research. 125 (3): 210–215. doi:10.1016/j.thromres.2009.11.028. PMC 2851158. PMID 20022081.
  8. ^ Beringer DX, Kroon-Batenburg LM (February 2013). "The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS". Acta Crystallographica Section F. 69 (Pt 2): 94–102. doi:10.1107/S1744309113000286. PMC 3564606. PMID 23385745.
  9. ^ Dementiev A, Silva A, Yee C, Li Z, Flavin MT, Sham H, et al. (March 2018). "Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors". Blood Advances. 2 (5): 549–558. doi:10.1182/bloodadvances.2018016337. PMC 5851424. PMID 29519898.
  10. ^ Pathak M, Wilmann P, Awford J, Li C, Hamad BK, Fischer PM, et al. (April 2015). "Coagulation factor XII protease domain crystal structure". Journal of Thrombosis and Haemostasis. 13 (4): 580–591. doi:10.1111/jth.12849. PMC 4418343. PMID 25604127.
  11. ^ Pathak M, Manna R, Li C, Kaira BG, Hamad BK, Belviso BD, et al. (June 2019). "Crystal structures of the recombinant β-factor XIIa protease with bound Thr-Arg and Pro-Arg substrate mimetics". Acta Crystallographica Section D. 75 (Pt 6): 578–591. doi:10.1107/S2059798319006910. PMID 31205020. S2CID 189944782.
  12. ^ Guyton AC, Hall JE. Textbook of Medical Physiology (PDF) (11th ed.). pp. 462–463. ISBN 0-7216-0240-1. Archived from the original (PDF) on 2020-07-14. Retrieved 2021-01-25.
  13. ^ Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C (November 2012). "In vivo roles of factor XII". Blood. 120 (22): 4296–4303. doi:10.1182/blood-2012-07-292094. PMC 3507141. PMID 22993391.
  14. ^ Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. (December 2009). "Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo". Cell. 139 (6): 1143–1156. doi:10.1016/j.cell.2009.11.001. PMC 2796262. PMID 20005807.
  15. ^ Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM, et al. (November 2010). "Polyphosphate exerts differential effects on blood clotting, depending on polymer size". Blood. 116 (20): 4353–4359. doi:10.1182/blood-2010-01-266791. PMC 2993633. PMID 20709905.
  16. ^ Verhoef J, Barendrecht A, Nickel KF, Dijkxhoorn K, Kenne E, Labberton L, et al. (January 2017). "Polyphosphate nanoparticles on the platelet surface trigger contact system activation". Blood. 129 (23): 1707–1717. doi:10.1182/blood-2016-08-734988. PMC 5364341. PMID 28049643.
  17. ^ Mailer RK, Allende M, Heestermans M, Schweizer M, Deppermann C, Frye M, et al. (March 2021). "Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate". Blood. 137 (10): 1392–1405. doi:10.1182/blood.2019004617. PMC 7955403. PMID 32932519.
  18. ^ Davoine C, Bouckaert C, Fillet M, Pochet L (December 2020). "Factor XII/XIIa inhibitors: Their discovery, development, and potential indications". European Journal of Medicinal Chemistry. 208: 112753. doi:10.1016/j.ejmech.2020.112753. hdl:2268/251278. PMID 32883641. S2CID 221496237.
  19. ^ a b c d e Wagenman BL, Townsend KT, Mathew P, Crookston KP (June 2009). "The laboratory approach to inherited and acquired coagulation factor deficiencies". Clinics in Laboratory Medicine. 29 (2): 229–252. doi:10.1016/j.cll.2009.04.002. PMID 19665676.
  20. ^ Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, et al. (July 2005). "Defective thrombus formation in mice lacking coagulation factor XII". The Journal of Experimental Medicine. 202 (2): 271–281. doi:10.1084/jem.20050664. PMC 2213000. PMID 16009717.
  21. ^ Kroll MH (2001). Manual of Coagulation Disorders. Blackwell Science. pp. 3–4, 206–207. ISBN 0-86542-446-2.
  22. ^ Göbel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, et al. (May 2016). "Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells". Nature Communications. 7: 11626. Bibcode:2016NatCo...711626G. doi:10.1038/ncomms11626. PMC 4873982. PMID 27188843.
  23. ^ Ratnoff OD, Margolius A (1955). "Hageman trait: an asymptomatic disorder of blood coagulation". Transactions of the Association of American Physicians. 68: 149–154. PMID 13299324.
  24. ^ Gordon EM, Gallagher CA, Johnson TR, Blossey BK, Ilan J (April 1990). "Hepatocytes express blood coagulation factor XII (Hageman factor)". The Journal of Laboratory and Clinical Medicine. 115 (4): 463–469. PMID 2324612.
  25. ^ Dee KC, Puleo DA, Bizios R, Madhavan G (2002). Tissue-biomaterial interactions. Hoboken: Wiley & Sons. ISBN 978-0-471-46112-8.
  26. ^ Trabattoni D, Montorsi P, Fabbiocchi F, Lualdi A, Gatto P, Bartorelli AL (August 2011). "A new kaolin-based haemostatic bandage compared with manual compression for bleeding control after percutaneous coronary procedures". European Radiology. 21 (8): 1687–1691. doi:10.1007/s00330-011-2117-3. PMID 21476127. S2CID 11755594.
  27. ^ Politi L, Aprile A, Paganelli C, Amato A, Zoccai GB, Sgura F, et al. (February 2011). "Randomized clinical trial on short-time compression with Kaolin-filled pad: a new strategy to avoid early bleeding and subacute radial artery occlusion after percutaneous coronary intervention". Journal of Interventional Cardiology. 24 (1): 65–72. doi:10.1111/j.1540-8183.2010.00584.x. hdl:11380/649198. PMID 20807305.
  28. ^ Wright JK, Kalns J, Wolf EA, Traweek F, Schwarz S, Loeffler CK, et al. (August 2004). "Thermal injury resulting from application of a granular mineral hemostatic agent". The Journal of Trauma. 57 (2): 224–230. doi:10.1097/01.ta.0000105916.30158.06. PMID 15345965.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Factor_XII&oldid=1256703449"